Skip to main content
. 2018 Nov 27;28(7):1076–1089. doi: 10.1093/hmg/ddy382

Figure 4.

Figure 4

muSRK-015P increases cortical bone thickness in SMN-C1 treated mice. Δ7 mice were treated with Low–High-dose or High-dose SMN-C1. At day 24 treatment with vehicle or 20 mg/kg muSRK-015 weekly was initiated. At day 52 tibias were collected for μCT analysis. (A) Cortical thickness. *P = 0.011; **P = 0.009. (B) Cross-sectional bone area. *P = 0.04. Significance determined by one-way ANOVA with Tukey’s Multiple Comparisons Test. N = 8 (Low–High muSRK-015P), 9 (Low–High Veh), 10 (WT, High Veh) or 15 (High muSRK-015P).